What’s Behind Intellia Therapeutics’ Stock Rally Today?

Intellia Therapeutics shares advanced 4.1% in pre-market trading as the U.S. Food and Drug Administration formally accepted the company’s Biologics License Application (BLA) for lonvoguran ziclumeran (lonvo-z), granting Priority Review with a PDUFA action date set for March 10, 2027.

In addition, the regulator said it presently has no intention of assembling an advisory committee to review the application—a procedural plus that eliminates an extra source of regulatory uncertainty surrounding the approval process.

The submission is backed by results from the Phase 3 HAELO study, which recruited 80 patients within nine months and demonstrated an 87% decrease in mean monthly hereditary angioedema (HAE) attacks for lonvo-z compared with placebo; 62% of treated patients stayed completely free of attacks and did not require prophylactic treatment over the six-month assessment window.

Contributing to the positive sentiment, Citizens analysts maintained their Market Outperform recommendation and $30.00 price target on the shares. Their sum-of-the-parts valuation assigns around $24 of per-share worth just to the HAE indication—highlighting the apparent disconnect between the current market price and lonvo-z’s potential commercial upside.

Broad-market cues were mixed and largely unhelpful: the S&P 500 slipped slightly, the Dow Jones also traded lower, while the NASDAQ posted a modest advance.

Elsewhere among gene-editing developers, Beam Therapeutics, Editas Medicine, and CRISPR Therapeutics issued no significant updates today, indicating that Intellia’s rally was driven mainly by its own regulatory milestone rather than a sector-wide sympathy boost.

Together, the FDA’s Priority Review status—which accelerates the typical review timeline—plus robust Phase 3 efficacy results and a favorable analyst view form a powerful near-term catalyst for NTLA shares.

Given a projected U.S. market entry in the first half of 2027 and the stock remaining significantly beneath its 52-week peak of $28.25, market participants seem to be adjusting their expectations for lonvo-z to become the first approved in-vivo CRISPR treatment globally.

This article was produced with AI assistance and reviewed by an editor. For further details, please refer to our Terms & Conditions.